Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene Lands Big CAR-T Deal With Juno – At A Big Price

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene is staking a leadership claim in immuno-oncology through a broad, 10-year collaboration with one of the leading CAR-T developers, Juno Therapeutics.

You may also be interested in...



Biogen's Singhal On Stepping Into R&D Leadership Shoes Amid Aduhelm Controversy

Priya Singhal took over as Biogen's top R&D leader on an interim basis after Al Sandrock’s unexpected retirement. "I understand that this is a challenging time," she told Scrip.

J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says

The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.

Merck's Gefapixant CRL Dashes Hopes For Another Near-Term Growth Driver

The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel